Base de dados : MEDLINE
Pesquisa : D12.776.543.750.705.852.420.380 [Categoria DeCS]
Referências encontradas : 376 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 38 ir para página                         

  1 / 376 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28406319
[Au] Autor:Antoniu SA
[Ad] Endereço:a Department of Medicine II-Nursing/Palliative Care , University of Medicine and Pharmacy Grigore T Popa Iasi, Romania , Iasi , Romania.
[Ti] Título:Benralizumab as a potential treatment of asthma.
[So] Source:Expert Opin Biol Ther;17(7):895-900, 2017 Jul.
[Is] ISSN:1744-7682
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Current anti-inflammatory asthma therapies including inhaled corticosteroids and leukotriene modifiers, are not always able to appropriately control the disease and other approaches are needed. These therapies specific target IgE (omalizumab) or IL-5 (mepolizumab). However, there is research underway investigating interleukin-based monoclonal antibodies such as benralizumab, an anti-IL-5R monoclonal antibody which is currently in phase III clinical development. Areas covered: This review summarizes the existing preclinical and clinical data of benralizumab. Data reviewed includes benralizumab's efficacy and safety data. The author also provides their expert opinion on this potential therapeutic and provide their perspectives for its future development. Expert opinion: Benralizumab was able to interfere significantly with disease-related morbidity and in particular with hospitalizations due to asthma exacerbation rates in a subset of patients with higher systemic eosinophil burden and higher doses of inhaled corticosteroids. The sustained inhibitory effect on eosinophilic inflammation might be an advantage which can be translated in less frequent dosing. Further attempts should be made to better define the asthma endotype in which such an antibody would be the most efficacious.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Asma/tratamento farmacológico
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/efeitos adversos
Anticorpos Monoclonais/imunologia
Anticorpos Monoclonais Humanizados/efeitos adversos
Anticorpos Monoclonais Humanizados/imunologia
Asma/patologia
Ensaios Clínicos como Assunto
Eosinófilos/imunologia
Seres Humanos
Vigilância de Produtos Comercializados
Receptores de Interleucina-5/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (Receptors, Interleukin-5); 71492GE1FX (benralizumab)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1080/14712598.2017.1319471


  2 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28364396
[Au] Autor:Shrimanker R; Pavord ID
[Ad] Endereço:Nuffield Department of Medicine, University of Oxford, NDM Research Building, Old Road Campus, Oxford, OX3 7FZ, UK.
[Ti] Título:Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.
[So] Source:BioDrugs;31(2):93-103, 2017 Apr.
[Is] ISSN:1179-190X
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:In this review, we outline the pathophysiology of severe asthma and discuss the role of anti-interleukin (IL)-5 inhibitors for the treatment of asthma. Anti-IL-5 treatments have shown efficacy in reducing the rate of severe asthma attacks in eosinophilic asthma. We review the history of the development of these agents, lessons learnt about severe asthma along the way and key clinical trials supporting efficacy of the three anti-IL-5 treatments that are clinically available or undergoing clinical trials in asthma.
[Mh] Termos MeSH primário: Antiasmáticos/farmacologia
Asma/tratamento farmacológico
Interleucina-5/antagonistas & inibidores
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados/farmacologia
Asma/fisiopatologia
Eosinófilos/efeitos dos fármacos
Eosinófilos/patologia
Seres Humanos
Terapia de Alvo Molecular/métodos
Receptores de Interleucina-5/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Antibodies, Monoclonal, Humanized); 0 (IL5 protein, human); 0 (Interleukin-5); 0 (Receptors, Interleukin-5); 35A26E427H (reslizumab); 71492GE1FX (benralizumab); 90Z2UF0E52 (mepolizumab)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170402
[St] Status:MEDLINE
[do] DOI:10.1007/s40259-017-0215-8


  3 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27796795
[Au] Autor:Giannetti MP; Cardet JC
[Ad] Endereço:Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 75 Francis St. Smith Building, 628, Boston, MA, 02115, USA.
[Ti] Título:Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
[So] Source:Curr Allergy Asthma Rep;16(11):80, 2016 Nov.
[Is] ISSN:1534-6315
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Asthma is the most common chronic respiratory disease in the USA. A subset of patients with asthma have refractory symptoms, persistent eosinophilic inflammation, and recurrent exacerbations despite maximal medical therapy. The monoclonal antibodies targeting the IL-5 pathway are a new class of medications designed to target severe eosinophilic asthma. There are two medications clinically available: mepolizumab and reslizumab, both of which target IL-5. A third medication, benralizumab, is currently under development and targets the IL-5 receptor. Clinical data suggest these medications can reduce asthma exacerbations and improve lung function in patients with peripheral eosinophilia and poorly controlled asthma despite maximal medical therapy. The anti-IL-5 medications are among the first targeted molecular therapies for asthma and will usher in an exciting new era in the treatment of severe asthma.
[Mh] Termos MeSH primário: Asma/tratamento farmacológico
Eosinofilia/metabolismo
Interleucina-5/antagonistas & inibidores
Receptores de Interleucina-5/metabolismo
[Mh] Termos MeSH secundário: Asma/imunologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Interleukin-5); 0 (Receptors, Interleukin-5)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE


  4 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27609406
[Au] Autor:FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M; CALIMA study investigators
[Ad] Endereço:The Lung Centre, Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, Canada. Electronic address: mark.fitzgerald@vch.ca.
[Ti] Título:Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
[So] Source:Lancet;388(10056):2128-2141, 2016 10 29.
[Is] ISSN:1474-547X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts. METHODS: In this randomised, double-blind, parallel-group, placebo-controlled, phase 3 study (CALIMA) undertaken at 303 sites in 11 countries, we enrolled patients aged 12-75 years with severe asthma uncontrolled by medium-dosage to high-dosage inhaled corticosteroids plus long-acting ß2-agonists (ICS plus LABA) and a history of two or more exacerbations in the previous year. Patients were randomly assigned (1:1:1) to receive 56 weeks of benralizumab 30 mg every 4 weeks (Q4W), benralizumab 30 mg every 8 weeks (Q8W; first three doses 4 weeks apart), or placebo (all subcutaneous injection). Patients were stratified (2:1) by baseline blood eosinophil counts 300 cells per µL or greater and less than 300 cells per µL, respectively. Patients and study centre staff were masked to treatment allocation. The primary endpoint was annual exacerbation rate ratio versus placebo for patients receiving high-dosage ICS plus LABA with baseline blood eosinophils 300 cells per µL or greater (intention-to-treat analysis). Key secondary endpoints were pre-bronchodilator forced expiratory volume in 1 s (FEV ) and total asthma symptom score. This study is registered with ClinicalTrials.gov, number NCT01914757. FINDINGS: Between Aug 21, 2013, and March 16, 2015, 2505 patients were enrolled, of whom 1306 patients were randomised; 425 patients were randomly assigned to and received benralizumab 30 mg Q4W, 441 to benralizumab 30 mg Q8W, and 440 to placebo. 728 patients were included in the primary analysis population. Benralizumab resulted in significantly lower annual exacerbation rates with the Q4W regimen (rate 0·60 [95% CI 0·48-0·74], rate ratio 0·64 [95% CI 0·49-0·85], p=0·0018, n=241) and Q8W regimen (rate 0·66 [95% CI 0·54-0·82], rate ratio 0·72 [95% CI 0·54-0·95], p=0·0188, n=239) compared with placebo (rate 0·93 [95% CI 0·77-1·12], n=248). Benralizumab also significantly improved pre-bronchodilator FEV (Q4W and Q8W) and total asthma symptom score (Q8W only) in these patients. The most common adverse events were nasopharyngitis (90 [21%] in the Q4W group, 79 [18%] in the Q8W group, and 92 [21%] in the placebo group) and worsening asthma (61 [14%] in the Q4W group, 47 [11%] in the Q8W group, and 68 [15%] in the group). INTERPRETATION: Benralizumab significantly reduced annual exacerbation rates and was generally well tolerated for patients with severe, uncontrolled asthma with blood eosinophils 300 cells per µL or greater. Our data further refine the patient population likely to receive the greatest benefit from benralizumab treatment. FUNDING: AstraZeneca and Kyowa Hakko Kirin.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Asma/tratamento farmacológico
Quimioterapia Combinada
Eosinofilia Pulmonar
[Mh] Termos MeSH secundário: Administração por Inalação
Corticosteroides/uso terapêutico
Adulto
Idoso
Antiasmáticos/uso terapêutico
Anticorpos Monoclonais Humanizados/efeitos adversos
Asma/complicações
Criança
Progressão da Doença
Relação Dose-Resposta a Droga
Método Duplo-Cego
Feminino
Volume Expiratório Forçado
Seres Humanos
Injeções Subcutâneas
Masculino
Meia-Idade
Eosinofilia Pulmonar/sangue
Receptores de Interleucina-5/antagonistas & inibidores
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Asthmatic Agents); 0 (Antibodies, Monoclonal, Humanized); 0 (Receptors, Interleukin-5); 71492GE1FX (benralizumab)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160910
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  5 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27254629
[Au] Autor:Lommatzsch M
[Ti] Título:[Treatment of refractory asthma with antibodies].
[Ti] Título:Therapie des refraktären Asthmas mit Antikörpern..
[So] Source:Dtsch Med Wochenschr;141(11):790-3, 2016 Jun.
[Is] ISSN:1439-4413
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:Current guidelines of the global initiative for asthma (GINA) recommend the addition of biologics in step 5 of the stepwise asthma treatment approach. This review gives an overview on the effects and the clinical role of antibodies targeting immunoglobulin E, IgE (Omalizumab), Interleukin-5, IL-5 (Mepolizumab, Reslizumab) or the IL-5 receptor (Benralizumab). In addition, potential future treatment options of refractory asthma with antibodies (for instance Dupilumab) are discussed.
[Mh] Termos MeSH primário: Antiasmáticos/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Asma/tratamento farmacológico
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados/uso terapêutico
Asma/imunologia
Fidelidade a Diretrizes
Seres Humanos
Imunoglobulina E/efeitos dos fármacos
Interleucina-5/antagonistas & inibidores
Omalizumab/efeitos adversos
Omalizumab/uso terapêutico
Medicina de Precisão
Receptores de Interleucina-5/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (IL5 protein, human); 0 (Interleukin-5); 0 (Receptors, Interleukin-5); 0 (SAR231893); 2P471X1Z11 (Omalizumab); 35A26E427H (reslizumab); 37341-29-0 (Immunoglobulin E); 71492GE1FX (benralizumab); 90Z2UF0E52 (mepolizumab)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160603
[St] Status:MEDLINE
[do] DOI:10.1055/s-0042-107044


  6 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27097165
[Au] Autor:Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y; Asian Benralizumab Study Group
[Ad] Endereço:Department of Allergy and Clinical Immunology, Ajou University Hospital, Suwon, Republic of Korea.
[Ti] Título:A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
[So] Source:Int Arch Allergy Immunol;169(3):135-45, 2016.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Airway eosinophils are considered to play an important role in the pathogenesis of asthma. Interleukin-5 is believed to be a key cytokine for the development, proliferation and activation of eosinophils. Benralizumab is an anti-interleukin-5 receptor α monoclonal antibody that depletes blood and airway eosinophils. We conducted a phase 2a study in South Korea and Japan to evaluate the effect of benralizumab in an East Asian population. The primary objective was to evaluate the effect of benralizumab in adults with uncontrolled eosinophilic asthma with 2-6 incidences of exacerbations in the past year using a medium/high dose of inhaled corticosteroids and long-acting ß2-agonists. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled study. The subjects (n = 106) were randomized into four groups: placebo (n = 27) or benralizumab 2 mg (n = 27), 20 mg (n = 26) and 100 mg (n = 26). Benralizumab or placebo were administered subcutaneously on weeks 0 (day 1), 4, 8, 16, 24, 32 and 40. The primary endpoint was the asthma exacerbation rate at week 52. RESULTS: The asthma exacerbation rate was reduced by 33, 45 or 36% versus the placebo group when treated with 2, 20 or 100 mg of benralizumab, respectively. The percent mean change in forced expiratory volume at 1 s increased with each of the three doses in subjects treated with benralizumab. CONCLUSIONS: Benralizumab reduced asthma exacerbation and improved lung function and asthma control in adults with uncontrolled eosinophilic asthma.
[Mh] Termos MeSH primário: Antiasmáticos/uso terapêutico
Anticorpos Monoclonais Humanizados/uso terapêutico
Asma/diagnóstico
Asma/tratamento farmacológico
Eosinófilos/patologia
Escarro
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antiasmáticos/administração & dosagem
Antiasmáticos/efeitos adversos
Anticorpos Monoclonais Humanizados/administração & dosagem
Anticorpos Monoclonais Humanizados/efeitos adversos
Biomarcadores
Progressão da Doença
Eosinófilos/efeitos dos fármacos
Eosinófilos/imunologia
Eosinófilos/metabolismo
Feminino
Seres Humanos
Japão
Contagem de Leucócitos
Masculino
Meia-Idade
Receptores de Interleucina-5/antagonistas & inibidores
República da Coreia
Testes de Função Respiratória
Escarro/citologia
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Antibodies, Monoclonal, Humanized); 0 (Biomarkers); 0 (Receptors, Interleukin-5); 71492GE1FX (benralizumab)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160421
[St] Status:MEDLINE
[do] DOI:10.1159/000444799


  7 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26859368
[Au] Autor:Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
[Ad] Endereço:aDepartment of Translational Medical Sciences, University of Naples Federico II, Naples bRespiratory Diseases and Allergy Clinic, DIMI-Department of Internal Medicine, Respiratory Diseases and Allergy Clinic, University of Genoa, IRCCS AOU S. Martino Genoa, Genoa cDepartment of Clinical and Experimental Medicine, Respiratory Disease and Allergology, University of Catania, Catania, Italy.
[Ti] Título:Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
[So] Source:Curr Opin Allergy Clin Immunol;16(2):186-200, 2016 Apr.
[Is] ISSN:1473-6322
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE OF REVIEW: Human eosinophils were first identified and named by Paul Ehrlich in 1879 on the basis of the cell's granular uptake of eosin. Although eosinophils represent approximately 1% of peripheral blood leukocytes, they have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophils and their mediators are critical effectors to asthma and eosinophilic granulomatosis with polyangiitis (EGPA). Eosinophils are equipped with a large number of cell-surface receptors and produce specific cytokines and chemokines. RECENT FINDINGS: Eosinophils are the major source of interleukin-5 and highly express the interleukin-5Rα on their surface. Clinical trials evaluating monoclonal antibodies to interleukin-5 (mepolizumab and reslizumab) and its receptor interleukin-5Rα (benralizumab) have been or are underway in patients with eosinophilic asthma, EGPA and chronic obstructive pulmonary disease (COPD). Overall, targeting interleukin-5/interleukin-5Rα is associated with a marked decrease in blood and sputum eosinophilia, the number of exacerbations and improvement of some clinical parameters in adult patients with severe eosinophilic asthma. Pilot studies suggest that mepolizumab might be a glucocorticoid-sparing treatment in patients with EGPA. A preliminary study found that benralizumab did not reduce the exacerbations and did modify lung function in patients with eosinophilic COPD. SUMMARY: The review examines recent advances in the biology of eosinophils and how targeting the interleukin-5 pathway might offer benefit to some patients with severe asthma, EGPA, and COPD. Interleukin-5/interleukin-5Rα-targeted treatments offer promises to patients with eosinophilic respiratory disorders.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/uso terapêutico
Asma/terapia
Eosinófilos/efeitos dos fármacos
Granulomatose com Poliangiite/terapia
Interleucina-5/imunologia
Doença Pulmonar Obstrutiva Crônica/terapia
Receptores de Interleucina-5/imunologia
[Mh] Termos MeSH secundário: Adulto
Animais
Asma/imunologia
Ensaios Clínicos como Assunto
Eosinófilos/imunologia
Granulomatose com Poliangiite/imunologia
Seres Humanos
Doença Pulmonar Obstrutiva Crônica/imunologia
Transdução de Sinais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Interleukin-5); 0 (Receptors, Interleukin-5)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160210
[St] Status:MEDLINE
[do] DOI:10.1097/ACI.0000000000000251


  8 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26653083
[Au] Autor:Fainardi V; Pisi G; Chetta A
[Ad] Endereço:Department of Clinical & Experimental Medicine, University Hospital, Parma, Italy.
[Ti] Título:Mepolizumab in the treatment of severe eosinophilic asthma.
[So] Source:Immunotherapy;8(1):27-34, 2016.
[Is] ISSN:1750-7448
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:IL-5 is crucial in the pathogenesis and evolution of eosinophilic asthma. Mepolizumab is a high-affinity humanized monoclonal antibody of the IgG1/k subtype that inhibits the binding of IL-5 to its receptor expressed on eosinophils, thereby inducing significant reduction in eosinophil circulation, as well as asthma exacerbations and corticosteroid treatment. This review deals with the currently available studies of mepolizumab in the treatment of patients with severe eosinophilic asthma.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Asma/terapia
Interleucina-5/imunologia
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados/metabolismo
Asma/imunologia
Asma/patologia
Eosinófilos/imunologia
Eosinófilos/metabolismo
Eosinófilos/patologia
Seres Humanos
Imunoterapia
Interleucina-5/antagonistas & inibidores
Interleucina-5/metabolismo
Receptores de Interleucina-5/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Interleukin-5); 0 (Receptors, Interleukin-5); 90Z2UF0E52 (mepolizumab)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151215
[St] Status:MEDLINE
[do] DOI:10.2217/imt.15.102


  9 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25388244
[Au] Autor:Gauvreau GM; Denburg JA
[Ad] Endereço:McMaster University, HSC-3U26, 1280 Main Street West, Hamilton, ON, Canada, L8S 4K1, gauvreau@mcmaster.ca.
[Ti] Título:Human mast cell and basophil/eosinophil progenitors.
[So] Source:Methods Mol Biol;1220:59-68, 2015.
[Is] ISSN:1940-6029
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mast cell, basophil, and eosinophil lineages all derive from CD34(+) hemopoietic stem cells; however, mast cells are derived from a distinct, nonmyeloid progenitor, while eosinophils and basophils share a common myeloid progenitor. These progenitors likely evolved from an ancestral leukocyte population involved in innate immunity and currently play a central role in the pathology of allergic disease. Advances in isolation and analysis of mast cell and basophil/eosinophil progenitor populations have been critical to understanding lineage commitment, differentiation, function, and transcriptional regulation of these cells and have provided a way of monitoring the effect of novel investigational therapies on these cell populations in samples of blood, bone marrow, and airway secretions.
[Mh] Termos MeSH primário: Basófilos/citologia
Eosinófilos/citologia
Mastócitos/citologia
Células-Tronco/citologia
[Mh] Termos MeSH secundário: Células da Medula Óssea/citologia
Sangue Fetal/citologia
Citometria de Fluxo
Seres Humanos
Metilcelulose/química
Receptores de Fator Estimulador das Colônias de Granulócitos e Macrófagos/metabolismo
Receptores de Interleucina-3/metabolismo
Receptores de Interleucina-5/metabolismo
Escarro/imunologia
Células-Tronco/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Granulocyte-Macrophage Colony-Stimulating Factor); 0 (Receptors, Interleukin-3); 0 (Receptors, Interleukin-5); 9004-67-5 (Methylcellulose)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:141112
[Lr] Data última revisão:
141112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141113
[St] Status:MEDLINE
[do] DOI:10.1007/978-1-4939-1568-2_4


  10 / 376 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24795292
[Au] Autor:Furuta GT; Atkins FD; Lee NA; Lee JJ
[Ad] Endereço:Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Children's Hospital Colorado, Aurora, Colorado; Gastrointestinal Eosinophilic Diseases Program, Children's Hospital Colorado, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of
[Ti] Título:Changing roles of eosinophils in health and disease.
[So] Source:Ann Allergy Asthma Immunol;113(1):3-8, 2014 Jul.
[Is] ISSN:1534-4436
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To review and highlight the unappreciated roles of eosinophils suggested by recent studies. DATA SOURCES: The literature, unpublished observations, and insights by the authors. STUDY SELECTIONS: Basic studies of mouse models and patient-based clinical studies of disease. RESULTS: Eosinophils are often thought of as destructive end-stage effector cells primarily linked to parasite host defense and dysregulated immune responses associated with allergic diseases, such as asthma. However, recent studies (ie, research focused on mechanisms of action and translational studies examining disease/inflammatory pathways) are suggesting far more complex roles for eosinophils. The goal of this review is 3-fold. (1) The authors examine the dynamic history of eosinophils and how physicians over time used this information to formulate defining hypotheses. Particular emphasis is placed on recent studies challenging the parochial view of host defense in favor of roles maintaining homeostasis through immune modulation and tissue remodeling/repair. (2) They discuss diagnostic approaches to assess eosinophils in clinical settings as a means of disease identification and subsequently as a measurement of disease severity. (3) They examine how contemporary views of eosinophils and their perceived roles in diseases have led to specific therapeutic strategies. The emphasis is to review the successes and failures of these strategies as the basis of formulating future clinical studies targeting eosinophils as potential therapies of disease. CONCLUSION: Despite the complexities of eosinophil-mediated activities and the less than overwhelming success of initial attempts targeting these cells, eosinophils remain a potentially important focal target of disease diagnosis and subsequent treatment strategies.
[Mh] Termos MeSH primário: Asma/imunologia
Dermatite Atópica/imunologia
Enterite/imunologia
Eosinofilia/imunologia
Eosinófilos/imunologia
Gastrite/imunologia
Síndrome Hipereosinofílica/imunologia
[Mh] Termos MeSH secundário: Animais
Antialérgicos/uso terapêutico
Asma/tratamento farmacológico
Asma/história
Asma/patologia
Movimento Celular/efeitos dos fármacos
Dermatite Atópica/tratamento farmacológico
Dermatite Atópica/história
Dermatite Atópica/patologia
Enterite/tratamento farmacológico
Enterite/história
Enterite/patologia
Eosinofilia/tratamento farmacológico
Eosinofilia/história
Eosinofilia/patologia
Eosinófilos/efeitos dos fármacos
Eosinófilos/patologia
Gastrite/tratamento farmacológico
Gastrite/história
Gastrite/patologia
História do Século XIX
História do Século XX
História do Século XXI
Seres Humanos
Síndrome Hipereosinofílica/tratamento farmacológico
Síndrome Hipereosinofílica/história
Síndrome Hipereosinofílica/patologia
Interleucina-5/antagonistas & inibidores
Interleucina-5/imunologia
Contagem de Leucócitos
Receptores de Interleucina-5/antagonistas & inibidores
Receptores de Interleucina-5/imunologia
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (IL5 protein, human); 0 (Interleukin-5); 0 (Receptors, Interleukin-5)
[Em] Mês de entrada:1408
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140506
[St] Status:MEDLINE



página 1 de 38 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde